AMAG Pharmaceuticals, Inc. and 3SBio, Inc. Announce Strategic Partnership to Develop and Commercialize Ferumoxytol in China
SHENYANG, China, May 28 /Xinhua-PRNewswire-FirstCall/ -- AMAG
Pharmaceuticals, Inc. (Nasdaq: AMAG ) and 3SBio, Inc. (Nasdaq: SSRX ), a
leading Chinese biotechnology company, today announced the signing of a
development and commercialization agreement for ferumoxytol, an intravenous
3SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2008 Results
...hree new product programs; 36,000 IU dosage formulation of EPIAO,
NuLeusin, and TPIAO label extension for the treatment of ITP.
-- Initiate ferumoxytol
registration trial in China, following US FDA
-- Submit application for clinical trials of NuPIAO, the Company's second
BioTrends Releases TreatmentTrends(TM): Nephrology and Renal Dietitians, Two Syndicated Reports Providing Continuing Insight into the Management of Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
...Venofer to increase following the news that Fresenius
will be marketing and distributing Venofer in dialysis units. Awareness of
AMAG Pharmaceutical's ferumoxytol
continues to be low. Among those familiar
with the product, expected benefits center around dosing and
administration, particularly for CKD patients. ...
3SBio Inc. Announces Second Quarter 2008 Results
...ess on the business
development front, notably, the initiation of a strategic partnership with
AMAG Pharmaceuticals, Inc. to develop and commercialize ferumoxytol
rapid progression of our phase III programs in our portfolio."
Second Quarter 2008 Unaudited Financial Results
Net Revenues. Our net reven...
BioTrends Releases Quarterly TreatmentTrends(TM): Nephrology Report Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
...e products to be differentiated, Venofer tends to
have a perceived advantage on ease of administration in both dialysis and
CKD. AMAG Pharmaceutical's ferumoxytol
could be commercially available by
the end of the year. Those with higher familiarity of the product, feel it
has a dosing and administration advantag...
BioTrends Releases Fourth Annual Nephrology TreatmentTrends Publication Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
...led an NDA for a new form of intravenous iron,
ferumoxytol, which could be commercially available in the second half of
2008. Current familiarity with ferumoxytol
is low, with 68% indicating that
they are "not at all familiar" with the product.
In the phosphate binder market, nephrologists seem to be in agreem...